Business
Change of Advisor
Change of Advisor.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n01/07/2009\n\nGB00B39J5N63\n\n Scancell Holdings Plc \n\n (`Scancell Holdings' or the `Company') \n\n Change of Advisor \n\nScancell Holdings Plc, the parent company of Scancell Limited (`Scancell'), the\ndeveloper of therapeutic cancer vaccines based on its patented ImmunoBody®\nplatform, announces today that it has appointed Zeus Capital as Corporate\nAdvisor to the Company with immediate effect.\n\nThe Directors of the issuer accept responsibility for this announcement.\n\n -ENDS- \n\nFor Further Information:\n\nProfessor Lindy Durrant Scancell Holdings Plc + 44 207 245 1100 \n \nAdam Reynolds/Vikki Krause Hansard Group + 44 7515 922906 \n \nRoss Andrews Zeus Capital + 44 (0)161 831 1512\n\nAbout Scancell\n\nScancell is developing novel therapeutic vaccines for the treatment of cancer\nand infectious diseases based on its groundbreaking ImmunoBody® technology\nplatform. Scancell's first cancer vaccine SCIB1 is being developed for the\ntreatment of melanoma and will enter clinical trials in early 2010.\n\nTreating cancer by vaccination allows small non-toxic doses of a vaccine to be\nadministered to a patient, stimulating an immune response. Effective cancer\nvaccines need to target dendritic cells to stimulate both parts of the cellular\nimmune system; the helper cell system where inflammation is stimulated at the\ntumour site; and the cytotoxic T-lymphocyte or CTL response where immune system\ncells are primed to recognise and kill specific cells.\n\nA limitation of many cancer vaccines currently in development is that they\ncannot specifically target dendritic cells in vivo. Several groups have\ndemonstrated successful vaccination by growing dendritic cells ex vivo, pulsing\nthem with tumour antigens and re-infusing them. However, this procedure is\npatient specific, time consuming and expensive. Scancell has developed its\nbreakthrough patent protected ImmunoBody® technology to overcome these\nlimitations.\n\nAn ImmunoBody® is a human antibody or fusion protein engineered to express\nhelper cell and CTL epitopes from tumour antigens over-expressed by cancer\ncells. Antibodies are ideal vectors for carrying T cell epitopes from tumour\nantigens as they have long half-lives and can effectively target dendritic\ncells via their Fc receptors, allowing efficient stimulation of both helper and\nCTL responses.\n\nThe Imm...